Entereg + Entereg + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Laparoscopic Colonic Resection
Conditions
Laparoscopic Colonic Resection
Trial Timeline
Nov 1, 2010 → Jul 1, 2015
NCT ID
NCT01258569About Entereg + Entereg + placebo
Entereg + Entereg + placebo is a phase 2 stage product being developed by Merck for Laparoscopic Colonic Resection. The current trial status is completed. This product is registered under clinical trial identifier NCT01258569. Target conditions include Laparoscopic Colonic Resection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01258569 | Phase 2 | Completed |
Competing Products
7 competing products in Laparoscopic Colonic Resection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 52 |
| SHR0410 Injection + SHR0410 Injection + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Rocuronium + Rocuronium | Merck | Approved | 85 |
| Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 | Merck | Approved | 85 |
| etoricoxib 120 mg | Merck | Approved | 85 |
| placebo + valdecoxib + valdecoxib | Pfizer | Phase 3 | 76 |
| N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo | Alkermes | Phase 3 | 74 |